nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—EPHA3—cleft lip	0.69	1	CbGaD
Bosutinib—SRC—periosteum—cleft lip	0.00236	0.0256	CbGeAlD
Bosutinib—CSF1R—periosteum—cleft lip	0.00212	0.023	CbGeAlD
Bosutinib—PHKG1—mouth—cleft lip	0.00164	0.0178	CbGeAlD
Bosutinib—PLK2—mouth—cleft lip	0.00135	0.0146	CbGeAlD
Bosutinib—EPHA4—tongue—cleft lip	0.00134	0.0146	CbGeAlD
Bosutinib—ULK3—tongue—cleft lip	0.00133	0.0144	CbGeAlD
Bosutinib—CDK2—embryo—cleft lip	0.00109	0.0118	CbGeAlD
Bosutinib—TLK1—telencephalon—cleft lip	0.00105	0.0114	CbGeAlD
Bosutinib—PRKCQ—telencephalon—cleft lip	0.00104	0.0113	CbGeAlD
Bosutinib—DSTYK—telencephalon—cleft lip	0.000974	0.0106	CbGeAlD
Bosutinib—EPHB2—telencephalon—cleft lip	0.000952	0.0103	CbGeAlD
Bosutinib—CASK—telencephalon—cleft lip	0.000952	0.0103	CbGeAlD
Bosutinib—EIF2AK1—telencephalon—cleft lip	0.000942	0.0102	CbGeAlD
Bosutinib—SRMS—telencephalon—cleft lip	0.000932	0.0101	CbGeAlD
Bosutinib—SIK1—mouth—cleft lip	0.000913	0.00991	CbGeAlD
Bosutinib—EPHA4—mouth—cleft lip	0.000904	0.00981	CbGeAlD
Bosutinib—ERBB3—mouth—cleft lip	0.000895	0.00971	CbGeAlD
Bosutinib—TNIK—telencephalon—cleft lip	0.000895	0.00971	CbGeAlD
Bosutinib—ULK3—mouth—cleft lip	0.000893	0.00969	CbGeAlD
Bosutinib—PTK2—mouth—cleft lip	0.000868	0.00942	CbGeAlD
Bosutinib—ALK—embryo—cleft lip	0.000868	0.00942	CbGeAlD
Bosutinib—WEE1—telencephalon—cleft lip	0.000842	0.00913	CbGeAlD
Bosutinib—DMPK—telencephalon—cleft lip	0.000842	0.00913	CbGeAlD
Bosutinib—ERBB4—embryo—cleft lip	0.000811	0.0088	CbGeAlD
Bosutinib—STK25—telencephalon—cleft lip	0.000804	0.00872	CbGeAlD
Bosutinib—ROCK1—embryo—cleft lip	0.000801	0.00869	CbGeAlD
Bosutinib—PLK2—telencephalon—cleft lip	0.000781	0.00848	CbGeAlD
Bosutinib—SIK3—telencephalon—cleft lip	0.000776	0.00842	CbGeAlD
Bosutinib—EPHB3—embryo—cleft lip	0.000772	0.00837	CbGeAlD
Bosutinib—MAST1—head—cleft lip	0.000736	0.00798	CbGeAlD
Bosutinib—STK24—telencephalon—cleft lip	0.00073	0.00792	CbGeAlD
Bosutinib—MAP2K1—embryo—cleft lip	0.000723	0.00785	CbGeAlD
Bosutinib—CSK—embryo—cleft lip	0.000719	0.00779	CbGeAlD
Bosutinib—EPHA5—telencephalon—cleft lip	0.000706	0.00766	CbGeAlD
Bosutinib—TYRO3—telencephalon—cleft lip	0.000706	0.00766	CbGeAlD
Bosutinib—TNK2—telencephalon—cleft lip	0.000678	0.00736	CbGeAlD
Bosutinib—PTK2B—embryo—cleft lip	0.000672	0.00729	CbGeAlD
Bosutinib—ERBB4—telencephalon—cleft lip	0.00066	0.00716	CbGeAlD
Bosutinib—TLK1—head—cleft lip	0.000656	0.00711	CbGeAlD
Bosutinib—ROCK1—telencephalon—cleft lip	0.000651	0.00707	CbGeAlD
Bosutinib—PRKCQ—head—cleft lip	0.000646	0.00701	CbGeAlD
Bosutinib—EPHA4—embryo—cleft lip	0.000645	0.00699	CbGeAlD
Bosutinib—ERBB3—embryo—cleft lip	0.000638	0.00692	CbGeAlD
Bosutinib—SIK2—head—cleft lip	0.000638	0.00692	CbGeAlD
Bosutinib—BMPR2—telencephalon—cleft lip	0.000633	0.00686	CbGeAlD
Bosutinib—EPHB3—telencephalon—cleft lip	0.000628	0.00681	CbGeAlD
Bosutinib—PKMYT1—head—cleft lip	0.000621	0.00674	CbGeAlD
Bosutinib—MERTK—telencephalon—cleft lip	0.00062	0.00673	CbGeAlD
Bosutinib—PTK2—embryo—cleft lip	0.000619	0.00672	CbGeAlD
Bosutinib—MAP4K4—telencephalon—cleft lip	0.000609	0.00661	CbGeAlD
Bosutinib—CLK3—head—cleft lip	0.000607	0.00658	CbGeAlD
Bosutinib—BCR—telencephalon—cleft lip	0.000605	0.00656	CbGeAlD
Bosutinib—MAP3K12—telencephalon—cleft lip	0.0006	0.00651	CbGeAlD
Bosutinib—RPS6KB1—embryo—cleft lip	0.000596	0.00646	CbGeAlD
Bosutinib—EPHB2—head—cleft lip	0.000593	0.00643	CbGeAlD
Bosutinib—PHKG1—head—cleft lip	0.000593	0.00643	CbGeAlD
Bosutinib—FGR—embryo—cleft lip	0.000592	0.00642	CbGeAlD
Bosutinib—MAP2K1—telencephalon—cleft lip	0.000588	0.00638	CbGeAlD
Bosutinib—CSNK1A1—telencephalon—cleft lip	0.000581	0.0063	CbGeAlD
Bosutinib—SRMS—head—cleft lip	0.00058	0.00629	CbGeAlD
Bosutinib—HCK—telencephalon—cleft lip	0.000577	0.00626	CbGeAlD
Bosutinib—CLK1—telencephalon—cleft lip	0.000577	0.00626	CbGeAlD
Bosutinib—TXK—head—cleft lip	0.000574	0.00623	CbGeAlD
Bosutinib—EPHA8—head—cleft lip	0.000568	0.00617	CbGeAlD
Bosutinib—CAMK2G—telencephalon—cleft lip	0.000566	0.00614	CbGeAlD
Bosutinib—LRRK2—telencephalon—cleft lip	0.000561	0.00609	CbGeAlD
Bosutinib—EGFR—telencephalon—cleft lip	0.000559	0.00607	CbGeAlD
Bosutinib—SYK—head—cleft lip	0.000557	0.00605	CbGeAlD
Bosutinib—CDK2—head—cleft lip	0.000552	0.00599	CbGeAlD
Bosutinib—FYN—embryo—cleft lip	0.000552	0.00599	CbGeAlD
Bosutinib—STK26—head—cleft lip	0.000547	0.00594	CbGeAlD
Bosutinib—PTK2B—telencephalon—cleft lip	0.000547	0.00593	CbGeAlD
Bosutinib—CSNK1E—telencephalon—cleft lip	0.000538	0.00584	CbGeAlD
Bosutinib—SIK1—telencephalon—cleft lip	0.00053	0.00575	CbGeAlD
Bosutinib—EPHA4—telencephalon—cleft lip	0.000524	0.00569	CbGeAlD
Bosutinib—WEE1—head—cleft lip	0.000524	0.00569	CbGeAlD
Bosutinib—DMPK—head—cleft lip	0.000524	0.00569	CbGeAlD
Bosutinib—ERBB3—telencephalon—cleft lip	0.000519	0.00563	CbGeAlD
Bosutinib—MAP2K2—telencephalon—cleft lip	0.000518	0.00562	CbGeAlD
Bosutinib—ULK3—telencephalon—cleft lip	0.000518	0.00562	CbGeAlD
Bosutinib—MAP3K2—telencephalon—cleft lip	0.000514	0.00558	CbGeAlD
Bosutinib—MAP3K7—telencephalon—cleft lip	0.000509	0.00553	CbGeAlD
Bosutinib—TBK1—telencephalon—cleft lip	0.000504	0.00546	CbGeAlD
Bosutinib—PTK2—telencephalon—cleft lip	0.000504	0.00546	CbGeAlD
Bosutinib—STK25—head—cleft lip	0.0005	0.00543	CbGeAlD
Bosutinib—EPHA3—head—cleft lip	0.000497	0.00539	CbGeAlD
Bosutinib—IRAK1—telencephalon—cleft lip	0.000494	0.00536	CbGeAlD
Bosutinib—PLK2—head—cleft lip	0.000487	0.00528	CbGeAlD
Bosutinib—RPS6KB1—telencephalon—cleft lip	0.000484	0.00525	CbGeAlD
Bosutinib—SIK3—head—cleft lip	0.000483	0.00524	CbGeAlD
Bosutinib—AXL—telencephalon—cleft lip	0.00048	0.0052	CbGeAlD
Bosutinib—SRC—embryo—cleft lip	0.000479	0.0052	CbGeAlD
Bosutinib—STK4—head—cleft lip	0.000465	0.00505	CbGeAlD
Bosutinib—SLK—telencephalon—cleft lip	0.000462	0.00501	CbGeAlD
Bosutinib—CAMK1D—head—cleft lip	0.00046	0.00499	CbGeAlD
Bosutinib—EPHB4—telencephalon—cleft lip	0.000458	0.00497	CbGeAlD
Bosutinib—STK24—head—cleft lip	0.000454	0.00493	CbGeAlD
Bosutinib—FYN—telencephalon—cleft lip	0.000449	0.00487	CbGeAlD
Bosutinib—FER—head—cleft lip	0.00044	0.00477	CbGeAlD
Bosutinib—TYRO3—head—cleft lip	0.00044	0.00477	CbGeAlD
Bosutinib—EPHA5—head—cleft lip	0.00044	0.00477	CbGeAlD
Bosutinib—ALK—head—cleft lip	0.00044	0.00477	CbGeAlD
Bosutinib—MAP4K5—telencephalon—cleft lip	0.000439	0.00476	CbGeAlD
Bosutinib—LYN—head—cleft lip	0.000437	0.00475	CbGeAlD
Bosutinib—MAP3K19—head—cleft lip	0.000431	0.00467	CbGeAlD
Bosutinib—CSF1R—embryo—cleft lip	0.00043	0.00467	CbGeAlD
Bosutinib—TNK2—head—cleft lip	0.000422	0.00458	CbGeAlD
Bosutinib—ERBB4—head—cleft lip	0.000411	0.00446	CbGeAlD
Bosutinib—STK3—head—cleft lip	0.000411	0.00446	CbGeAlD
Bosutinib—ROCK1—head—cleft lip	0.000406	0.0044	CbGeAlD
Bosutinib—YES1—telencephalon—cleft lip	0.000405	0.00439	CbGeAlD
Bosutinib—TAOK3—telencephalon—cleft lip	0.0004	0.00434	CbGeAlD
Bosutinib—BMPR2—head—cleft lip	0.000394	0.00427	CbGeAlD
Bosutinib—STK36—head—cleft lip	0.000391	0.00424	CbGeAlD
Bosutinib—EPHB3—head—cleft lip	0.000391	0.00424	CbGeAlD
Bosutinib—SRC—telencephalon—cleft lip	0.00039	0.00423	CbGeAlD
Bosutinib—MERTK—head—cleft lip	0.000386	0.00419	CbGeAlD
Bosutinib—PDGFRB—embryo—cleft lip	0.000381	0.00414	CbGeAlD
Bosutinib—MAP4K4—head—cleft lip	0.000379	0.00411	CbGeAlD
Bosutinib—BCR—head—cleft lip	0.000377	0.00408	CbGeAlD
Bosutinib—MAP3K12—head—cleft lip	0.000374	0.00406	CbGeAlD
Bosutinib—MAP2K1—head—cleft lip	0.000366	0.00397	CbGeAlD
Bosutinib—STK35—head—cleft lip	0.000366	0.00397	CbGeAlD
Bosutinib—CSK—head—cleft lip	0.000364	0.00395	CbGeAlD
Bosutinib—CSNK1A1—head—cleft lip	0.000362	0.00392	CbGeAlD
Bosutinib—CLK1—head—cleft lip	0.000359	0.0039	CbGeAlD
Bosutinib—HCK—head—cleft lip	0.000359	0.0039	CbGeAlD
Bosutinib—MAP2K5—telencephalon—cleft lip	0.000358	0.00389	CbGeAlD
Bosutinib—CAMK2G—head—cleft lip	0.000353	0.00383	CbGeAlD
Bosutinib—BMP2K—head—cleft lip	0.000353	0.00383	CbGeAlD
Bosutinib—CSF1R—telencephalon—cleft lip	0.00035	0.00379	CbGeAlD
Bosutinib—LRRK2—head—cleft lip	0.000349	0.00379	CbGeAlD
Bosutinib—PTK2B—head—cleft lip	0.000341	0.00369	CbGeAlD
Bosutinib—ABL1—embryo—cleft lip	0.00034	0.00369	CbGeAlD
Bosutinib—CSNK1E—head—cleft lip	0.000335	0.00363	CbGeAlD
Bosutinib—SIK1—head—cleft lip	0.00033	0.00358	CbGeAlD
Bosutinib—IRAK4—head—cleft lip	0.00033	0.00358	CbGeAlD
Bosutinib—EPHA4—head—cleft lip	0.000326	0.00354	CbGeAlD
Bosutinib—ERBB3—head—cleft lip	0.000323	0.00351	CbGeAlD
Bosutinib—MAP2K2—head—cleft lip	0.000322	0.0035	CbGeAlD
Bosutinib—ULK3—head—cleft lip	0.000322	0.0035	CbGeAlD
Bosutinib—MAP3K2—head—cleft lip	0.00032	0.00347	CbGeAlD
Bosutinib—PTK2—head—cleft lip	0.000314	0.0034	CbGeAlD
Bosutinib—TBK1—head—cleft lip	0.000314	0.0034	CbGeAlD
Bosutinib—PDGFRB—telencephalon—cleft lip	0.00031	0.00337	CbGeAlD
Bosutinib—RPS6KB1—head—cleft lip	0.000302	0.00327	CbGeAlD
Bosutinib—FGR—head—cleft lip	0.0003	0.00325	CbGeAlD
Bosutinib—AXL—head—cleft lip	0.000299	0.00324	CbGeAlD
Bosutinib—EPHA2—head—cleft lip	0.00028	0.00304	CbGeAlD
Bosutinib—FYN—head—cleft lip	0.000279	0.00303	CbGeAlD
Bosutinib—ABL1—telencephalon—cleft lip	0.000277	0.003	CbGeAlD
Bosutinib—MAP3K3—head—cleft lip	0.000273	0.00296	CbGeAlD
Bosutinib—MAP4K5—head—cleft lip	0.000273	0.00296	CbGeAlD
Bosutinib—YES1—head—cleft lip	0.000252	0.00274	CbGeAlD
Bosutinib—STK10—head—cleft lip	0.00025	0.00271	CbGeAlD
Bosutinib—TAOK3—head—cleft lip	0.000249	0.0027	CbGeAlD
Bosutinib—SRC—head—cleft lip	0.000243	0.00263	CbGeAlD
Bosutinib—MAP2K5—head—cleft lip	0.000223	0.00242	CbGeAlD
Bosutinib—CSF1R—head—cleft lip	0.000218	0.00236	CbGeAlD
Bosutinib—PDGFRB—head—cleft lip	0.000193	0.0021	CbGeAlD
Bosutinib—ABL1—head—cleft lip	0.000172	0.00187	CbGeAlD
Bosutinib—ABCB1—embryo—cleft lip	0.000106	0.00115	CbGeAlD
Bosutinib—ABCB1—telencephalon—cleft lip	8.6e-05	0.000933	CbGeAlD
Bosutinib—ABCB1—head—cleft lip	5.35e-05	0.000581	CbGeAlD
Bosutinib—CSK—Disease—MYC—cleft lip	4.27e-06	1.96e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—FGFR2—cleft lip	4.27e-06	1.96e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—FGF3—cleft lip	4.24e-06	1.95e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—FGFR2—cleft lip	4.24e-06	1.95e-05	CbGpPWpGaD
Bosutinib—BCR—Signaling Pathways—MYC—cleft lip	4.24e-06	1.95e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—FGF10—cleft lip	4.24e-06	1.95e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—FGF9—cleft lip	4.23e-06	1.94e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—FGFR1—cleft lip	4.23e-06	1.94e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—FGFR3—cleft lip	4.21e-06	1.94e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—FGFR2—cleft lip	4.19e-06	1.93e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—FGF10—cleft lip	4.18e-06	1.92e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—FGF3—cleft lip	4.18e-06	1.92e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—FGF2—cleft lip	4.16e-06	1.91e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—FGF2—cleft lip	4.16e-06	1.91e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—FGF3—cleft lip	4.16e-06	1.91e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—FGF2—cleft lip	4.15e-06	1.91e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—FGF9—cleft lip	4.14e-06	1.9e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—FGFR1—cleft lip	4.14e-06	1.9e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—FGFR1—cleft lip	4.14e-06	1.9e-05	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—FGF2—cleft lip	4.14e-06	1.9e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—FGFR1—cleft lip	4.12e-06	1.9e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—NOS3—cleft lip	4.1e-06	1.89e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—SPRY2—cleft lip	4.1e-06	1.89e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—FGF7—cleft lip	4.1e-06	1.89e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—FGFR2—cleft lip	4.09e-06	1.88e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—FGF10—cleft lip	4.09e-06	1.88e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—FGF9—cleft lip	4.07e-06	1.87e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—FGFR3—cleft lip	4.06e-06	1.87e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—FGF9—cleft lip	4.05e-06	1.86e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—FGFR1—cleft lip	4.04e-06	1.86e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—MTHFR—cleft lip	4.03e-06	1.85e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—NOS3—cleft lip	4.02e-06	1.85e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—FGFR1—cleft lip	4.02e-06	1.85e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—FGF2—cleft lip	4.01e-06	1.84e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—FGFR3—cleft lip	3.99e-06	1.84e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—FGFR1—cleft lip	3.99e-06	1.83e-05	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—FGF2—cleft lip	3.99e-06	1.83e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PTCH1—cleft lip	3.98e-06	1.83e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—FGFR1—cleft lip	3.98e-06	1.83e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—FGF2—cleft lip	3.96e-06	1.82e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—FGFR1—cleft lip	3.95e-06	1.82e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—FGFR2—cleft lip	3.94e-06	1.81e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—MTHFR—cleft lip	3.93e-06	1.81e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—FGF10—cleft lip	3.92e-06	1.8e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—FGFR2—cleft lip	3.92e-06	1.8e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—FGFR3—cleft lip	3.91e-06	1.8e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—FGFR3—cleft lip	3.91e-06	1.8e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—FGFR1—cleft lip	3.9e-06	1.79e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—FGFR3—cleft lip	3.9e-06	1.79e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PTCH1—cleft lip	3.84e-06	1.76e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—FGF2—cleft lip	3.82e-06	1.76e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—FGFR3—cleft lip	3.82e-06	1.76e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—FGFR2—cleft lip	3.81e-06	1.75e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—FGFR1—cleft lip	3.81e-06	1.75e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—FGFR3—cleft lip	3.8e-06	1.75e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—MTHFR—cleft lip	3.79e-06	1.74e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—FGF8—cleft lip	3.78e-06	1.74e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—NOS3—cleft lip	3.77e-06	1.73e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—MTHFR—cleft lip	3.77e-06	1.73e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—FGFR3—cleft lip	3.77e-06	1.73e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—FGFR3—cleft lip	3.76e-06	1.73e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—FGFR2—cleft lip	3.76e-06	1.73e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—FGF2—cleft lip	3.75e-06	1.73e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—FGFR3—cleft lip	3.74e-06	1.72e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—TCN2—cleft lip	3.73e-06	1.72e-05	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—MYC—cleft lip	3.71e-06	1.7e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—FGFR3—cleft lip	3.69e-06	1.7e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—FGFR2—cleft lip	3.68e-06	1.69e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—FGF2—cleft lip	3.67e-06	1.69e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—FGFR1—cleft lip	3.67e-06	1.69e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—FGF10—cleft lip	3.65e-06	1.68e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—FGFR1—cleft lip	3.65e-06	1.68e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—FGF10—cleft lip	3.62e-06	1.66e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—FGF3—cleft lip	3.61e-06	1.66e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—FGFR3—cleft lip	3.6e-06	1.66e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Disease—MYC—cleft lip	3.57e-06	1.64e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—FGF10—cleft lip	3.56e-06	1.64e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—FGFR2—cleft lip	3.56e-06	1.64e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—FGFR2—cleft lip	3.55e-06	1.63e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—FGFR1—cleft lip	3.55e-06	1.63e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—FGF2—cleft lip	3.53e-06	1.62e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—FGF2—cleft lip	3.53e-06	1.62e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—FGF9—cleft lip	3.52e-06	1.62e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—FGFR1—cleft lip	3.5e-06	1.61e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—FGF10—cleft lip	3.49e-06	1.61e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—FGF3—cleft lip	3.48e-06	1.6e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—FGFR3—cleft lip	3.47e-06	1.6e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—FGFR3—cleft lip	3.45e-06	1.59e-05	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—cleft lip	3.44e-06	1.58e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—FGF10—cleft lip	3.44e-06	1.58e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—FGFR1—cleft lip	3.43e-06	1.58e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—FGF10—cleft lip	3.42e-06	1.57e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—FGFR2—cleft lip	3.4e-06	1.56e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PTCH1—cleft lip	3.4e-06	1.56e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—FGF9—cleft lip	3.39e-06	1.56e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—FGFR3—cleft lip	3.36e-06	1.54e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—FGFR2—cleft lip	3.35e-06	1.54e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—FGFR1—cleft lip	3.32e-06	1.53e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—FGFR1—cleft lip	3.31e-06	1.52e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—FGFR3—cleft lip	3.31e-06	1.52e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—FGF2—cleft lip	3.3e-06	1.52e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—FGFR2—cleft lip	3.28e-06	1.51e-05	CbGpPWpGaD
Bosutinib—HCK—Disease—MYC—cleft lip	3.27e-06	1.51e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—MTHFR—cleft lip	3.27e-06	1.51e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—NOS3—cleft lip	3.26e-06	1.5e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—FGF2—cleft lip	3.26e-06	1.5e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—FGFR3—cleft lip	3.25e-06	1.49e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—NOS3—cleft lip	3.21e-06	1.48e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—FGFR1—cleft lip	3.17e-06	1.46e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—MTHFR—cleft lip	3.16e-06	1.45e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—MYC—cleft lip	3.15e-06	1.45e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—FGFR2—cleft lip	3.14e-06	1.45e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—FGFR3—cleft lip	3.14e-06	1.44e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—FGF2—cleft lip	3.14e-06	1.44e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—FGFR3—cleft lip	3.13e-06	1.44e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—FGFR1—cleft lip	3.13e-06	1.44e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—NOS3—cleft lip	3.09e-06	1.42e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—MYC—cleft lip	3.09e-06	1.42e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—MYC—cleft lip	3.09e-06	1.42e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—FGF2—cleft lip	3.09e-06	1.42e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—MYC—cleft lip	3.08e-06	1.42e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—FGF3—cleft lip	3.08e-06	1.42e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—FGFR1—cleft lip	3.06e-06	1.41e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—FGF2—cleft lip	3.02e-06	1.39e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—FGF2—cleft lip	3.02e-06	1.39e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—FGF2—cleft lip	3.01e-06	1.39e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—FGF9—cleft lip	3e-06	1.38e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—FGFR3—cleft lip	3e-06	1.38e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—MYC—cleft lip	2.99e-06	1.37e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—NOS3—cleft lip	2.98e-06	1.37e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—NOS3—cleft lip	2.98e-06	1.37e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—FGF10—cleft lip	2.97e-06	1.37e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—FGFR3—cleft lip	2.96e-06	1.36e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—FGF2—cleft lip	2.95e-06	1.36e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—FGF2—cleft lip	2.94e-06	1.35e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—FGFR2—cleft lip	2.93e-06	1.35e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—FGFR1—cleft lip	2.93e-06	1.35e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—FGF2—cleft lip	2.91e-06	1.34e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—FGF2—cleft lip	2.9e-06	1.34e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—FGFR2—cleft lip	2.9e-06	1.34e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—FGFR3—cleft lip	2.89e-06	1.33e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—FGF2—cleft lip	2.89e-06	1.33e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—NOS3—cleft lip	2.87e-06	1.32e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—FGFR2—cleft lip	2.86e-06	1.32e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—FGF10—cleft lip	2.86e-06	1.32e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—FGF2—cleft lip	2.85e-06	1.31e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—NOS3—cleft lip	2.81e-06	1.29e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—FGFR2—cleft lip	2.8e-06	1.29e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—MTHFR—cleft lip	2.79e-06	1.29e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—FGF2—cleft lip	2.78e-06	1.28e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SLC19A1—cleft lip	2.77e-06	1.28e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—FGFR3—cleft lip	2.77e-06	1.27e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—FGFR2—cleft lip	2.76e-06	1.27e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—FGFR2—cleft lip	2.74e-06	1.26e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—NOS3—cleft lip	2.74e-06	1.26e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—FGFR1—cleft lip	2.73e-06	1.26e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—MYC—cleft lip	2.72e-06	1.25e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—FGFR1—cleft lip	2.71e-06	1.24e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—FGF2—cleft lip	2.68e-06	1.23e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—FGFR1—cleft lip	2.67e-06	1.23e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—FGF2—cleft lip	2.67e-06	1.23e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—NOS3—cleft lip	2.64e-06	1.22e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—NOS3—cleft lip	2.63e-06	1.21e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—FGFR1—cleft lip	2.61e-06	1.2e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—FGF2—cleft lip	2.59e-06	1.19e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—MTR—cleft lip	2.59e-06	1.19e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—FGFR3—cleft lip	2.58e-06	1.19e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—FGFR1—cleft lip	2.57e-06	1.18e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—NOS3—cleft lip	2.56e-06	1.18e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—FGF2—cleft lip	2.56e-06	1.18e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—FGFR3—cleft lip	2.56e-06	1.18e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—FGFR1—cleft lip	2.56e-06	1.18e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—FGF10—cleft lip	2.53e-06	1.16e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—NOS3—cleft lip	2.52e-06	1.16e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—FGFR3—cleft lip	2.52e-06	1.16e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—FGF2—cleft lip	2.51e-06	1.15e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—MYC—cleft lip	2.5e-06	1.15e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—FGFR3—cleft lip	2.47e-06	1.13e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—FGFR3—cleft lip	2.43e-06	1.12e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—FGF2—cleft lip	2.43e-06	1.12e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—FGF2—cleft lip	2.42e-06	1.11e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—FGFR3—cleft lip	2.42e-06	1.11e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—NOS3—cleft lip	2.39e-06	1.1e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—FGFR2—cleft lip	2.38e-06	1.1e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—FGF2—cleft lip	2.32e-06	1.07e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TCN2—cleft lip	2.3e-06	1.06e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—FGFR2—cleft lip	2.3e-06	1.06e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—NOS3—cleft lip	2.28e-06	1.05e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—FGF2—cleft lip	2.28e-06	1.05e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—NOS3—cleft lip	2.25e-06	1.04e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—FGF2—cleft lip	2.23e-06	1.03e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—FGFR1—cleft lip	2.22e-06	1.02e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—NOS3—cleft lip	2.2e-06	1.01e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—MYC—cleft lip	2.16e-06	9.94e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—FGF2—cleft lip	2.14e-06	9.84e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—FGFR1—cleft lip	2.14e-06	9.84e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—MYC—cleft lip	2.13e-06	9.79e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—FGFR3—cleft lip	2.1e-06	9.65e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—MYC—cleft lip	2.05e-06	9.43e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—FGFR2—cleft lip	2.03e-06	9.35e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—FGFR3—cleft lip	2.02e-06	9.3e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—FGF2—cleft lip	2e-06	9.18e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—FGF2—cleft lip	1.98e-06	9.09e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—MYC—cleft lip	1.98e-06	9.09e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—MYC—cleft lip	1.98e-06	9.09e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NOS3—cleft lip	1.97e-06	9.05e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—NOS3—cleft lip	1.95e-06	8.96e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—FGF2—cleft lip	1.95e-06	8.96e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NOS3—cleft lip	1.92e-06	8.83e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—FGF2—cleft lip	1.91e-06	8.77e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—MYC—cleft lip	1.9e-06	8.76e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—FGFR1—cleft lip	1.89e-06	8.71e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NOS3—cleft lip	1.88e-06	8.65e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—FGF2—cleft lip	1.88e-06	8.63e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—FGF2—cleft lip	1.87e-06	8.59e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—MYC—cleft lip	1.86e-06	8.57e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NOS3—cleft lip	1.85e-06	8.52e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NOS3—cleft lip	1.84e-06	8.47e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—MYC—cleft lip	1.82e-06	8.36e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—FGFR3—cleft lip	1.79e-06	8.24e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—MYC—cleft lip	1.75e-06	8.06e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—MYC—cleft lip	1.74e-06	8.02e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MYC—cleft lip	1.7e-06	7.8e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MYC—cleft lip	1.67e-06	7.69e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—FGF2—cleft lip	1.62e-06	7.46e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NOS3—cleft lip	1.6e-06	7.36e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—MTR—cleft lip	1.59e-06	7.33e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MYC—cleft lip	1.59e-06	7.29e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—TYMS—cleft lip	1.58e-06	7.29e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—FGF2—cleft lip	1.56e-06	7.19e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NOS3—cleft lip	1.54e-06	7.09e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—MYC—cleft lip	1.51e-06	6.96e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MYC—cleft lip	1.49e-06	6.87e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MYC—cleft lip	1.46e-06	6.71e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—MTHFR—cleft lip	1.38e-06	6.37e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—FGF2—cleft lip	1.38e-06	6.36e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NOS3—cleft lip	1.36e-06	6.28e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MYC—cleft lip	1.3e-06	6e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MYC—cleft lip	1.29e-06	5.94e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MYC—cleft lip	1.27e-06	5.86e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MYC—cleft lip	1.25e-06	5.73e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MYC—cleft lip	1.23e-06	5.64e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MYC—cleft lip	1.22e-06	5.61e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MYC—cleft lip	1.06e-06	4.88e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MYC—cleft lip	1.02e-06	4.7e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TYMS—cleft lip	9.76e-07	4.49e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—NOS3—cleft lip	9.65e-07	4.44e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MYC—cleft lip	9.05e-07	4.16e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—MTHFR—cleft lip	8.53e-07	3.92e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NOS3—cleft lip	5.95e-07	2.74e-06	CbGpPWpGaD
